| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.6 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.024 | 0.6 |